XML 59 R44.htm IDEA: XBRL DOCUMENT
v3.20.2

Summary of Significant Accounting Policies - Schedule of Intangible Assets (Detail) - USD ($) | 3 Months Ended | 12 Months Ended |
--- | --- | --- | ---
Sep. 26, 2020 | Mar. 28, 2020 | Dec. 28, 2019 | Mar. 30, 2019 | Sep. 28, 2019 | Oct. 01, 2018
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Gross Carrying Value | $ 4,931,100,000 |  |  |  | $ 4,786,600,000 |
Accumulated Amortization | 3,623,600,000 |  |  |  | 3,326,800,000 |
Impairment charge |  |  | $ 30,200,000 | $ 685,400,000 |  |
Developed technology |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Gross Carrying Value | 4,054,000,000.0 |  |  |  | 3,927,700,000 |
Accumulated Amortization | 2,907,200,000 |  |  |  | 2,654,800,000 |
Customer relationships |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Gross Carrying Value | 549,100,000 |  |  |  | 525,500,000 |
Accumulated Amortization | 477,800,000 |  |  |  | 447,500,000 |
Trade names |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Gross Carrying Value | 245,500,000 |  |  |  | 245,400,000 |
Accumulated Amortization | 181,200,000 |  |  |  | 171,100,000 |
Distribution agreement |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Gross Carrying Value | 0 |  |  |  | 2,500,000 |
Accumulated Amortization | 0 |  |  |  | 0 |
Non-competition agreements |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Gross Carrying Value | 1,500,000 |  |  |  | 1,400,000 |
Accumulated Amortization | 1,300,000 |  |  |  | 900,000 |
Business licenses |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Gross Carrying Value | 2,400,000 |  |  |  | 2,300,000 |
Accumulated Amortization | 2,300,000 |  |  |  | 2,200,000 |
Acquired intangible assets [Member] |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Gross Carrying Value | 4,852,500,000 |  |  |  | 4,704,800,000 |
Accumulated Amortization | 3,569,800,000 |  |  |  | 3,276,500,000 |
Internal-use software [Member] |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Gross Carrying Value | 51,800,000 |  |  |  | 53,900,000 |
Accumulated Amortization | 43,200,000 |  |  |  | 43,400,000 |
Capitalized software [Member] |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Gross Carrying Value | 26,800,000 |  |  |  | 27,900,000 |
Accumulated Amortization | 10,600,000 |  |  |  | 6,900,000 |
Medical Aesthetics |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Impairment charge |  | $ 30,200,000 |  |  |  |
Medical Aesthetics | Developed Technology [Member] |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Impairment charge | 576,900,000 | 24,100,000 |  |  |  |
Medical Aesthetics | Customer relationships |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Impairment charge | 22,400,000 | 900,000 |  |  |  |
Medical Aesthetics | Trade names |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Impairment charge | 48,600,000 | $ 2,000,000.0 |  |  |  |
Medical Aesthetics | Property, Plant and Equipment [Member] |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Impairment charge | 9,800,000 |  |  |  |  |
Focal Therapeutics | Developed technology |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Identifiable intangible assets: |  |  |  |  |  | $ 83,100,000
Focal Therapeutics | In-process research and development |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Identifiable intangible assets: |  |  |  |  |  | 11,400,000
In process research and development reclassified to developed technology |  |  |  |  | $ 5,500,000 |
Focal Therapeutics | Trade names |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Identifiable intangible assets: |  |  |  |  |  | $ 2,700,000
Acessa Health [Member] | Developed technology |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Identifiable intangible assets: | 127,000,000.0 |  |  |  |  |
Acessa Health [Member] | Trade names |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Identifiable intangible assets: | $ 1,200,000 |  |  |  |  |

X
- Definition In process research and development reclassified to developed technology + References No definition available. + Details
Name: | holx_Inprocessresearchanddevelopmentreclassifiedtodevelopedtechnology
Namespace Prefix: | holx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228 + Details
Name: | us-gaap_AssetImpairmentCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of intangible assets, excluding goodwill, acquired at the acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 928 -SubTopic 340 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=holx_CustomerRelationshipsContractsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=holx_BusinessLicensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=holx_AcquiredintangibleassetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=holx_InternalusesoftwareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=holx_CapitalizedsoftwareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=holx_MedicalAestheticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=holx_DevelopedTechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=us-gaap_CustomerRelationshipsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=us-gaap_TradeNamesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=holx_FocalTherapeuticsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=holx_AcessaHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |